Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Research output: Contribution to journal › Journal article › Research › peer-review
Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.
| Original language | English |
|---|---|
| Journal | Current Opinion in Investigational Drugs |
| Volume | 9 |
| Issue number | 4 |
| Pages (from-to) | 402-13 |
| Number of pages | 11 |
| ISSN | 1472-4472 |
| Publication status | Published - 2008 |
Bibliographical note
Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Humans; Hypoglycemic Agents; Molecular Structure; Patents as Topic; Piperidines; Structure-Activity Relationship; Treatment Outcome; Uracil
ID: 8416764